120 related articles for article (PubMed ID: 25268071)
1. BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities.
Berghoff AS; Preusser M
Curr Opin Neurol; 2014 Dec; 27(6):689-96. PubMed ID: 25268071
[TBL] [Abstract][Full Text] [Related]
2. BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors.
Preusser M; Bienkowski M; Birner P
Expert Opin Investig Drugs; 2016; 25(1):7-14. PubMed ID: 26536389
[TBL] [Abstract][Full Text] [Related]
3. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
[TBL] [Abstract][Full Text] [Related]
4. BRAF alterations in primary brain tumors.
Maraka S; Janku F
Discov Med; 2018 Aug; 26(141):51-60. PubMed ID: 30265855
[TBL] [Abstract][Full Text] [Related]
5. Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.
Kowalewski A; Durślewicz J; Zdrenka M; Grzanka D; Szylberg Ł
Target Oncol; 2020 Aug; 15(4):531-540. PubMed ID: 32648041
[TBL] [Abstract][Full Text] [Related]
6. Clinical neuropathology practice news 2-2012: BRAF V600E testing.
Capper D; Berghoff AS; von Deimling A; Preusser M
Clin Neuropathol; 2012; 31(2):64-6. PubMed ID: 22385786
[TBL] [Abstract][Full Text] [Related]
7. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of disseminated pilocytic astrocytomas.
Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
[TBL] [Abstract][Full Text] [Related]
10. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
[TBL] [Abstract][Full Text] [Related]
11. Targeting BRAF in pediatric brain tumors.
Kieran MW
Am Soc Clin Oncol Educ Book; 2014; ():e436-40. PubMed ID: 24857135
[TBL] [Abstract][Full Text] [Related]
12. KIAA1549:BRAF fusion gene in pediatric brain tumors of various histogenesis.
Antonelli M; Badiali M; Moi L; Buttarelli FR; Baldi C; Massimino M; Sanson M; Giangaspero F
Pediatr Blood Cancer; 2015 Apr; 62(4):724-7. PubMed ID: 25382612
[TBL] [Abstract][Full Text] [Related]
13. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
14. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma.
Koelsche C; Sahm F; Paulus W; Mittelbronn M; Giangaspero F; Antonelli M; Meyer J; Lasitschka F; von Deimling A; Reuss D
Neuropathol Appl Neurobiol; 2014 Apr; 40(3):337-44. PubMed ID: 23822828
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.
Capper D; Berghoff AS; Magerle M; Ilhan A; Wöhrer A; Hackl M; Pichler J; Pusch S; Meyer J; Habel A; Petzelbauer P; Birner P; von Deimling A; Preusser M
Acta Neuropathol; 2012 Feb; 123(2):223-33. PubMed ID: 22012135
[TBL] [Abstract][Full Text] [Related]
17. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
18. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
Tosuner Z; Geçer MÖ; Hatiboğlu MA; Abdallah A; Turna S
Oncol Lett; 2018 Aug; 16(2):2402-2408. PubMed ID: 30013630
[TBL] [Abstract][Full Text] [Related]
20. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms.
Go H; Jeon YK; Huh J; Choi SJ; Choi YD; Cha HJ; Kim HJ; Park G; Min S; Kim JE
Histopathology; 2014 Aug; 65(2):261-72. PubMed ID: 24720374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
